Vor Biopharma (VOR) Cash from Investing Activities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Cash from Investing Activities data on file, last reported at -$263.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 114350.87% year-over-year to -$263.2 million in Q1 2026; TTM through Mar 2026 was -$311.8 million, a 692.18% decrease from a year earlier, with the FY2025 full-year figure at -$48.8 million, down 150.39% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$263.2 million, down from -$49.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for VOR reached as high as $53.0 million in Q2 2024 and fell as low as -$263.2 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$14.0 million across 5 years, with a median of -$34000.0 in 2024.
• Across the five-year window, Cash from Investing Activities soared 604.77% in 2023 and plunged 114350.87% in 2026, its largest moves.
• Year by year, Cash from Investing Activities stood at -$97.0 million in 2022, then soared by 110.65% to $10.3 million in 2023, then sank by 100.7% to -$72000.0 in 2024, then sank by 67919.44% to -$49.0 million in 2025, then tumbled by 437.5% to -$263.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$263.2 million in Q1 2026, -$49.0 million in Q4 2025, and -$244000.0 in Q3 2025.